Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedAug 30, 2025
DataAggregated Company Financials
Companies551
  • 7D-1.8%
  • 3M9.8%
  • 1Y-10.0%
  • YTD4.4%

Over the last 7 days, the Biotech industry has dropped 1.8%, driven by a pullback from Amgen of 2.0%. The industry has fallen 10.0% in the last year. Looking forward, earnings are forecast to grow by 26% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 30 Aug 2025US$1.1tUS$163.6b-US$18,635,211,382.3715.4x-56.7x6.5x
Mon, 28 Jul 2025US$992.7bUS$155.1b-US$22,919,892,186.1514.8x-43.3x6.4x
Wed, 25 Jun 2025US$932.9bUS$155.9b-US$23,877,765,865.0216.7x-39.1x6x
Fri, 23 May 2025US$907.8bUS$155.9b-US$24,354,722,512.9815.6x-37.3x5.8x
Sun, 20 Apr 2025US$756.8bUS$119.2b-US$36,619,881,205.0719.4x-20.7x6.3x
Tue, 18 Mar 2025US$839.1bUS$118.4b-US$37,618,768,555.5419.9x-22.3x7.1x
Thu, 13 Feb 2025US$815.2bUS$118.2b-US$35,533,913,315.5717x-22.9x6.9x
Sat, 11 Jan 2025US$967.2bUS$149.4b-US$26,283,970,082.7116.6x-36.8x6.5x
Mon, 09 Dec 2024US$1.0tUS$150.0b-US$26,481,489,967.0117.9x-39.1x6.9x
Wed, 06 Nov 2024US$1.1tUS$148.1b-US$30,555,050,448.5116.6x-34.9x7.2x
Fri, 04 Oct 2024US$891.6bUS$113.2b-US$35,958,059,033.0822x-24.8x7.9x
Sun, 01 Sep 2024US$909.4bUS$113.1b-US$35,712,101,098.3824x-25.5x8x
Tue, 30 Jul 2024US$1.2tUS$164.9b-US$28,963,503,229.8326.8x-43x7.5x
Thu, 27 Jun 2024US$1.2tUS$164.4b-US$27,986,453,486.3427.7x-41.4x7x
Sat, 25 May 2024US$1.1tUS$164.6b-US$26,747,196,206.4323.8x-42.1x6.8x
Mon, 22 Apr 2024US$1.1tUS$164.2b-US$23,311,155,066.5220.4x-45.9x6.5x
Wed, 20 Mar 2024US$1.2tUS$167.4b-US$21,814,367,317.9113.8x-53.5x7x
Fri, 16 Feb 2024US$1.2tUS$169.1b-US$20,723,712,339.7018.7x-55.6x6.8x
Sun, 14 Jan 2024US$1.4tUS$204.8b-US$22,497,556,941.0018.8x-63.9x7x
Tue, 12 Dec 2023US$1.3tUS$204.6b-US$22,091,146,901.0018.7x-58.6x6.3x
Thu, 09 Nov 2023US$1.2tUS$204.1b-US$20,943,935,957.0016.6x-59.3x6.1x
Sat, 07 Oct 2023US$1.3tUS$207.4b-US$13,060,168,797.0017.2x-96.3x6.1x
Mon, 04 Sep 2023US$1.3tUS$207.6b-US$12,421,503,459.0018.4x-104.2x6.2x
Wed, 02 Aug 2023US$1.1tUS$186.2b-US$14,964,083,330.0014.7x-76.4x6.1x
Fri, 30 Jun 2023US$1.1tUS$186.2b-US$16,044,205,476.0013.6x-69.4x6x
Sun, 28 May 2023US$1.1tUS$185.9b-US$16,045,698,796.0011.2x-69.9x6x
Tue, 25 Apr 2023US$1.2tUS$198.6b-US$3,172,070,914.0013.7x-374.7x6x
Thu, 23 Mar 2023US$1.1tUS$199.5b-US$3,522,273,239.0012.4x-313.9x5.5x
Sat, 18 Feb 2023US$1.2tUS$202.6b-US$64,851,937.0016.5x-17785.7x5.7x
Mon, 16 Jan 2023US$1.2tUS$203.7bUS$1.8b14.5x670.9x5.8x
Wed, 14 Dec 2022US$1.2tUS$202.9bUS$1.5b14.8x792.8x5.8x
Fri, 11 Nov 2022US$1.1tUS$201.7bUS$975.9m14.1x1133.1x5.5x
Sun, 09 Oct 2022US$1.0tUS$206.1bUS$5.4b14.9x190.3x5x
Tue, 06 Sep 2022US$1.0tUS$206.1bUS$6.1b14.6x171.4x5x
Price to Earnings Ratio

171.4x


Total Market Cap: US$1.0tTotal Earnings: US$6.1bTotal Revenue: US$206.1bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 39.3x202320242025
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.4x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 7.4% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-0.0093%
Healthcare-0.82%
Biotech-1.85%
Biotech-1.85%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
INSM InsmedUS$136.103.2%
+US$892.0m		78.0%PS72.3x
MENS Jyong BiotechUS$54.8119.2%
+US$654.0m		n/aPE-1347.7x
MDGL Madrigal PharmaceuticalsUS$437.855.6%
+US$516.4m		77.2%PS18.9x
BBIO BridgeBio PharmaUS$51.765.5%
+US$512.3m		85.9%PS42x
NBIX Neurocrine BiosciencesUS$139.603.1%
+US$413.6m		9.9%PE39.8x

Latest News

NTRA
US$168.25
Natera
7D
1.6%
1Y
42.3%
MDGL
US$437.85
Madrigal Pharmaceuticals
7D
5.6%
1Y
77.2%

US Patent And EU Expansion Will Secure Future Potential

The consensus analyst price target for Madrigal Pharmaceuticals was raised from $449.57 to $461.43, primarily driven by the EU approval and expanded patent protection for Rezdiffra, which de-risks future cash flows and supports robust sales expectations in a large addressable market. Analyst Commentary Bullish analysts updated their models to reflect the recent EU approval of Rezdiffra, reducing risk and subsequently lowering the discount rate applied to future cash flows.
GILD
US$112.97
Gilead Sciences
7D
-1.6%
1Y
43.0%
AMGN
US$287.71
Amgen
7D
-2.0%
1Y
-13.8%
BIIB
US$132.22
Biogen
7D
-5.1%
1Y
-35.4%
BBIO
US$51.76
BridgeBio Pharma
7D
5.5%
1Y
85.9%
INSM
US$136.10
Insmed
7D
3.2%
1Y
78.0%

Brensocatib's 2025 Launch Will Transform Bronchiectasis Care

Insmed’s consensus price target has surged to $148.44, driven by the FDA approval and strong commercial prospects for Brinsupri, expanded pipeline potential, and robust Phase 2 results for TPIP—underscoring significant upward revisions in revenue and profit expectations. Analyst Commentary Bullish analysts are raising price targets following FDA approval of Brinsupri as the first therapy for non-cystic fibrosis bronchiectasis, citing a broad label with both doses approved, clean safety profile, and inclusion of favorable FEV1 and secondary endpoint data in prescribing information.
ALNY
US$446.51
Alnylam Pharmaceuticals
7D
-1.7%
1Y
70.0%
BNTX
US$100.00
BioNTech
7D
-9.8%
1Y
13.4%
SMMT
US$23.70
Summit Therapeutics
7D
-9.5%
1Y
82.6%
NBIX
US$139.60
Neurocrine Biosciences
7D
3.1%
1Y
9.9%
VRTX
US$391.02
Vertex Pharmaceuticals
7D
-1.0%
1Y
-21.1%
RVMD
US$37.97
Revolution Medicines
7D
2.6%
1Y
-10.9%
MRNA
US$24.09
Moderna
7D
-11.2%
1Y
-68.9%
MTSR
US$35.29
Metsera
7D
6.8%
1Y
n/a

Metsera (NASDAQ:MTSR) Is In A Good Position To Deliver On Growth Plans

Jul 31
Metsera (NASDAQ:MTSR) Is In A Good Position To Deliver On Growth Plans